Decoding mitochondrial genes in pediatric AML and development of a novel prognostic mitochondrial gene signature

Shilpi Chaudhary[1], Shuvadeep Ganguly[1], Jayanth Kumar Palanichamy[2], Archna Singh[2], Dibyabhaba Pradhan[3], Radhika Bakhshi[4], Anita Chopra[5], Sameer Bakhshi[1]

[1]Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
[2]Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
[3]ICMR Computational Genomics Centre, Indian Council of Medical Research, New Delhi, India
[4]Shaheed Rajguru College of Applied Sciences for Women, University of Delhi, Delhi, India
[5]Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, India.

Corresponding author:
Prof. Sameer Bakhshi
Department of Medical Oncology
Dr. B.R.A. Institute Rotary Cancer Hospital
All India Institute of Medical Sciences,
New Delhi – 110029, INDIA
Email: sambakh@hotmail.com
Office Phone Number: +91-11-29575237
Fax Number: +91-11-26588153

Abstract Word Count: 250
Text Word Count: 5063
No. of Tables: 8
No. of Figures: 12
Supplementary files: 1 (Supplementary Tables: 6)
No. of References: 52
Running title: Mitochondria-related prognostic gene signature in AML

Abstract

Background

Gene expression profile of mitochondrial-related genes is not well deciphered in pediatric acute myeloid leukaemia (AML). We aimed to identify mitochondria-related differentially expressed genes (DEGs) in pediatric AML with their prognostic significance.

Methods

Children with *de novo* AML were included prospectively between July 2016-December 2019. Transcriptomic profiling was done for a subset of samples, stratified by mtDNA copy number. Top mitochondria-related DEGs were identified and validated by real-time PCR. A prognostic gene signature risk score was formulated using DEGs independently predictive of overall survival (OS) in multivariable analysis. Predictive ability of the risk score was estimated along with external validation in The Tumor Genome Atlas (TCGA) AML dataset.

Results

In 143 children with AML, twenty mitochondria-related DEGs were selected for validation, of which 16 were found to be significantly dysregulated. Upregulation of *SDHC* ($p<0.001$), *CLIC1* ($p=0.013$) and downregulation of *SLC25A29* ($p<0.001$) were independently predictive of inferior OS, and included for developing prognostic risk score. The risk score model was independently predictive of survival over and above ELN risk categorization (Harrell's c-index: 0.675). High-risk patients (risk score above median) had significantly inferior OS ($p<0.001$) and event free survival ($p<0.001$); they were associated with poor-risk cytogenetics ($p=0.021$), ELN intermediate/poor risk group ($p=0.016$), absence of RUNX1-RUNX1T1

(p=0.027), and not attaining remission (p=0.016). On external validation, the risk score also predicted OS (p=0.019) in TCGA dataset.

Conclusion

We identified and validated mitochondria-related DEGs with prognostic impact in pediatric AML and also developed a novel 3-gene based externally validated gene signature predictive of survival.

Keywords: Acute Myeloid Leukaemia, Mitochondria, Gene signature, RNA sequencing, Child

Introduction

Despite recent advancements, the survival in pediatric acute myeloid leukaemia (AML) continues to remain dismal(1). Various molecular and genetic alterations are frequently used for risk stratification, identification of therapeutic targets as well as predicting disease prognosis in AML(2). Whole genome and transcriptome sequencing have been extensively used in AML to identify potential novel molecular targets and developing prognostic gene signatures to predict survival, relapse and risk stratification(3–5). However, data on potential mitochondrial genes with impact on AML are limited.

Dysregulation of mitochondrial pathways have been implicated in pathogenesis and progression of various malignancies(6). Multiple studies have reported the role of mitochondrial DNA (mtDNA) mutations, metabolic pathways and oxidative phosphorylation, on disease biology and prognosis of AML(7,8). We have previously reported the relationship of mutations in mtDNA regulatory region with mitochondrial gene expression, and their impact on survival in children with AML(9–11). Considering the impact of mitochondrial pathways in outcome of AML, it is important to explore tumor cell heterogeneity in AML with respect to mitochondrial transcriptome and identify potential therapeutic or prognostic molecular targets.

Recently, we have reported that high mtDNA copy number is associated with poor outcome in paediatric AML and also identified its potential regulation through *PGC1A*(12). In the current study, among children with AML stratified according to mtDNA copy number, we identified mitochondria-related differentially expressed genes (DEGs) through whole transcriptome sequencing. We further validated the topmost identified mitochondria-related DEGs in a cohort of paediatric AML patients and formulated a prognostic mitochondrial gene signature for predicting survival outcome. We then validated this gene signature in an

external cohort of adult AML patients from The Cancer Genome Atlas (TCGA) dataset along with estimation of predictive ability of the developed prognostic gene signature.

Methodology

Study design, patient population, treatment and clinical follow up

This was a prospective observational cohort study that included consecutive *de novo* paediatric (≤18 years) patients with AML registered from July 2016 to December 2019 at medical oncology outpatient clinic of our cancer centre. The workflow of the study is depicted in figure 1. Study was ethically approved by institute ethics committee (IEC/NP-336/2012, IECPG-79/22.03.2017) and informed consent was taken from care givers and assent was obtained from all participants (≥8 years). Patients with granulocytic sarcoma without marrow involvement, acute promyelocytic leukaemia, and mixed phenotypic acute leukaemia were excluded. Fifty age-matched patients of solid malignancies without marrow involvement were also enrolled as controls. Remission status and survival outcomes were noted.

Risk Assessment by karyotyping and mutation analysis

Conventional cytogenetics were done at baseline to identify translocations, inversions, deletion as well as other chromosomal abnormalities for risk stratification of pediatric AML. Mutation profiling of *RUNX1-RUNX1T1* (Runt-related transcription factor 1-RUNX1 partner transcriptional co-repressor 1 fusion transcript), *CBFB-MYH11* (Core binding factor beta-myosin heavy chain 11 fusion transcript), FLT3-ITD (Fms like tyrosine kinase 3-internal tandem duplication), and *NPM1* (Nucleophosmin 1) by reverse transcriptase polymerase chain reaction (PCR) were performed at baseline for risk assessment as per European LeukemiaNet (ELN) recommendation (13).

Treatment protocol

All patients were treated with uniform induction protocol, i.e., 3+7 regimen including daunorubicin 60 mg/m^2 day 1-3 and cytarabine 100mg/m^2 continuous infusion day 1-7. Consolidation therapy with three cycles of high dose cytarabine at 18g/m^2 were given to patients after achieving complete remission (CR) whereas repeated induction with ADE regimen (cytarabine: 100 mg/m2 twice daily, day 1-10; daunorubicin: 50 mg/m2, day 1-3; and etoposide: 100 mg/m2, day 1-5) were used for refractory or relapse cases. Patients at CR2 underwent allogeneic hematopoietic stem cell transplantation with matched sibling donor if available (13,14).

Isolation of bone marrow mononuclear cells (BMMCs), DNA and RNA extraction and quantification

BMMCs were isolated by Ficoll-Hypaque (Sigma diagnostics, USA) density gradient centrifugation followed by isolation of total RNA and DNA. Briefly, BM samples collected from all the patients and controls were layered onto the histopaque in 15 ml falcon tube followed by centrifugation at 400g for 30 min at room temperature. The mononuclear cells layer was carefully taken out after centrifugation and washed twice with phosphate buffer saline (PBS). BMMC were then stored for DNA isolation using isopropanol precipitation method and total RNA was isolated using TRIzol method as per manufacturer's protocols. Quality of DNA and RNA was checked by Nanodrop 1000 (Thermo Fisher) and integrity of RNA was checked by TapeStation (Agilent).

Estimation of mitochondrial DNA copy number

Relative mtDNA copy number was assessed by fluorescent DNA binding dye SYBR based quantitative real time PCR using, with Roche Light Cycler 480 II. The relative mitochondrial DNA copy number was normalized to expression of nuclear gene *ACTB,* which was chosen as a nuclear housekeeping gene. The mitochondrial DNA copy number, normalized to copies

per cell, in each subject and control sample was calculated using the following formula: 2^[Ct(β−actin) −Ct (minor arc)] (Ct being respective cycle thresholds). Relative mitochondrial DNA copy numbers of patients were then compared with controls.

Whole transcriptome sequencing, identification of differentially expressed genes (DEG) and selection of DEG for analysis

All the samples were classified into three separate groups based on relative mtDNA copy number(12). Patients were categorized into: AMLCN_H (mtDNA copy number ≥ 75th percentile), AMLCN_I (mtDNA copy number 50th to 75th percentile) and AMLCN_L (mtDNA copy number < 50th percentile) groups. A subset of samples was randomly selected from each of the three sub-groups and controls with RNA integrity score above 7 and a total of 15 samples (12 patients including 3 from AMLCN_H group, 4 from AMLCN_I group, 5 from AMLCN_L group and 3 controls) were sent for whole transcriptome profiling for the identification of DEGs compared to controls.

Library Construction and sequencing

The sequencing library was prepared by random fragmentation of the cDNA sample, followed by 5' and 3' adapter ligation, after end-repair and the addition of an ‘A’ base and SPRI clean-up. The prepared cDNA library was amplified using PCR for the enrichment of the adapter-ligated fragments. The individual libraries were quantified using a NanoDrop spectrophotometer (Thermo Scientific) and validated for quality with a Bioanalyzer (Agilent Technologies). Adapter-ligated fragments were then PCR amplified and gel purified. cDNA library was used for sequencing which was carried out on Illumina Hiseq 4000 NGS platform.

Processing of the reads and differential expression analysis

The quality of raw reads was first checked by FastQC version v0.11.8. Trimmomatic was performed to remove adapter sequences and low-quality reads for further analysis. The trimmed reads were then aligned to reference Human genome (hg38) using HISAT2 tool. SAM tool was used to convert SAM files into BAM files which was used for quantification and estimation of aligned reads by StringTie (v2.0.6). Lastly differential expression analysis was performed by limma Bioconductor package (version 3.48.1). Absolute fold change value ≥ 2 (a $\geq$ two-fold change in expression, either upregulated or downregulated) and adjusted p value ($q \leq 0.05$) threshold was used for the identification of differentially expressed genes (DEGs). Volcano plots were made with log fold change; p value and adjusted p value of the transcripts were calculated using devtools in R package (version 3.6.1). Gene name of the corresponding transcripts with significant p value, adjusted p value and log 2-fold difference compared to controls, were fetched using gProfilerR library in R package. Exclusive differentially expressed genes were identified among the groups by making Venn diagram using Venny (Venny 2.1) online tool. (Figure 2).

Construction of protein-protein interaction network, determination of HUB genes and MCODE analysis

A interactive network of proteins encoded DEGs present in the respective groups were constructed using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (15) in Cytoscape. Cytohubba plugin was used for identifying Hub genes among the whole interactome network. Those genes which got enriched using at least six different topological algorithms among Degree, Edge Percolated Component (EPC), Maximum Neighbourhood Component (MNC), Density of Maximum Neighbourhood Component (DMNC), Maximal Clique Centrality (MCC) and centralities based on shortest paths, such as Bottleneck (BN), Eccentricity, Closeness, Radiality, Betweenness, and Stress were considered as Hub genes(16). Cytoscape plug-in MCODE clustering algorithm was used for

identifying the maximum ranked cluster which has a highly interconnected region , also known as seed nodes as well as their neighbour nodes in the whole network (17). Subcellular location of the genes was identified from the gene ontology table. Compartment mitochondria score was used for selecting mitochondrial related genes among all the AML subgroups.

Selection and validation of mitochondria-related DEGs

Out of all identified DEGs from transcriptome sequencing, mitochondria-related genes were filtered using Cytoscape compartment mitochondrion score (0 being minimum and 5 being highest)(18). DEGs with topmost mitochondrial compartment score were selected for validation in a cohort of paediatric patients with AML. The genes of MCODE cluster 1 and Hub genes were assessed for their mitochondrial localization as above and genes in each group with highest mitochondrial compartment score were selected for validation. Based on these selection strategies, a total of 20 mitochondria-related DEGs were selected for validation. Real time PCR was performed to validate the selected mitochondria-related genes using specific primers (Table S1) and the gene expressions were quantified per previously described protocol(12). All experiments were replicated in triplicates.

Comparison of validated mitochondria-related DEGs in TCGA data set

For external validation of mitochondrial related DEGs, the RNA-sequencing data (Illumina HiSeq 2000) of TCGA adult AML(LAML) dataset was chosen, which is one of the largest datasets of transcriptomic profile in AML with recorded clinical outcome(https://www.cbioportal.org/ study/summary? id=laml_tcga). The adult dataset was specifically chosen to see the impact of prognostic impact of the validated mitochondria-related age group in a different age group as well. The expression of validated DEGs was compared with LAML data set using online available GEPIA2 (Gene Expression Profiling Interactive Analysis) web server (http://gepia2.cancer-pku.cn/#index)(19).

Statistical Methods

Prognostic impact of mitochondria-related DEGs and development of mitochondrial gene signature

Statistical analysis was carried out in SPSS (v23, IBM, NY, USA). Descriptive statistics were used to summarize baseline characteristics. Gene expression was reported as median values with interquartile ranges. Gene expression values and clinical continuous variables with non-parametric distribution were compared by Mann Whitney test. Clinical categorical variables were compared by Chi-square test/Fisher's exact test as applicable. Alpha error was adjusted for multiple comparisons by Bonferroni correction. Kaplan Meier method was used to analyse time to event outcomes. Duration from enrolment to relapse or death due to any cause was considered as event free survival (EFS). Time from enrolment to death due to any cause was defined as overall survival (OS). Survival data was censored till 31st Dec 2020. The follow-up estimation was done by reverse Kaplan Meier method.

Prognostic impact of all validated DEGs on OS of the whole validation cohort was performed by multivariable Cox regression analysis in a forward stepwise manner based on log likelihood change. Validated DEGs with significant ($p<0.05$) predictive impact on OS in multivariable analysis were included for the prognostic gene signature model. The proportional hazard assumption was assessed by Schoenfeld global test. Internal validation of the multivariable prognostic model was carried out by bootstrapping method (10000 resampling) and genes that did not satisfy bootstrapping validation were excluded. A prognostic risk score was generated using cox regression coefficient Beta (β) values of included genes, of the final multivariable model as below:

$$\text{Risk score} = \left[\sum_{k=0}^{n} \binom{n}{k} \{\beta_k \times (Expression\ mRNA_k)\}\right] \times 100$$

The area under the time-dependent receiver operating characteristic (ROC) curve (Timed AUC) for 12-months and 18-months survival was estimated and Harrel's C-index of the prognostic model was calculated using the R package "survminor" in R (version 4.0.3). Patients were classified into two groups based on their risk score above (High-risk) and below (Low-risk) the median. The survival outcomes of the patients were compared between high-risk score vs low-risk score patients using Kaplan Meier analysis to evaluate the prognostic significance of the gene signature model.

Impact of clinical features and independent prognostic value of the gene signature

The role of demographic and clinical features, including gender, age, haemoglobin, hyperleukocytosis (≥50000/µl), platelet count, presence of chloroma and ELN risk stratification(2)on survival outcome was analysed using the Cox regression. Factors with $p<0.1$ in univariable analysis were included for multivariable Cox regression in a forward stepwise manner using log likelihood change. Clinico-demographic factors which were significant in multivariable analysis were included in a multivariable Cox regression model along with gene signature risk score to explore the independent predictive value of gene signature. The timed AUC using 12-months survival and 18-months survival as the outcome and Harrel's C-index of the clinical prognostic model and combined clinical and gene signature prognostic model were compared for identifying the additional prognostic benefits of gene signature over clinical parameters. The impact of mtDNA copy number on survival outcome was also analysed similarly.

External validation of mitochondrial prognostic gene signature in TCGA dataset

The prognostic impact of our gene signature risk score on OS was done in TCGA LAML (n=179) dataset by Cox regression analysis. Patients were similarly sub-grouped into high-risk and low-risk category based on median value of the gene signature; the survival outcomes of the patients were compared between high-risk score vs low-risk score patients

using Kaplan Meier analysis and timed AUC of 12-month and 18-month survival was evaluated. Based on available karyotyping data, patients of the TCGA dataset were grouped into poor-risk karyotype and others (including good and intermediate-risk karyotype). The karyotype category and mitochondrial gene risk score were assessed for their impact on OS by a multivariable Cox regression model to explore the independent predictive value of the gene signature in the external cohort as well.

Results

Patients' recruitment and baseline clinical features

Total 170 patients were enrolled, out of which 27 patients (5 patients were AML M3, 4 had granulocytic sarcoma without marrow involvement, and 18 patients had insufficient samples) were excluded. The baseline demographic and clinical characteristics of final 143 patients are summarized in Table 1. Median age was 10 years (range: 0.8-18 years) and 50% of the patients were classified as ELN good risk. Total 104 patients (72.7%) achieved complete remission (CR) after induction therapy. At median follow-up of 36 months (32.67-39.33 months), the median OS was 21.93 months (13.54–30.31months). The clinical characteristics of the TCGA LAML dataset are summarized in Table S2.

Identification of DEGs in paediatric AML based on mtDNA copy number

We identified 898,769, and 953 significantly dysregulated transcripts in AMLCN_H, AMLCN_I and AMLCN_L groups respectively by whole transcriptome sequencing as represented in volcano plots (Figure3). Majority of genes were found significantly downregulated in all three groups whereas the number of dysregulated genes were higher in AMLCN_H group compared to other two groups. A total of 351 DEGs (59 upregulated and 292 downregulated) were identified in AMLCN_H. Similarly, AMLCN_I and AMLCN_L groups had 290 (66 upregulated and 224 downregulated) and 332 (47 upregulated and 285 downregulated) DEGs respectively as compared to controls.

Identification of mitochondria-related DEGs, hub genes and selection of genes for validation

Out of all DEGs, 78, 58, and 71 mitochondria-related DEGs were identified in AMLCN_H, AMLCN_I and AMLCN_L groups respectively. Among them, 35 genes were common in all three subgroups, whereas 18, 12 and 14 mitochondria-related DEGs were exclusively present in AMLCN_H, AMLCN_I and AMLCN_L groups respectively (Figure 4). In AMLCN_H, AMLCN_I and AMLCN_L groups, we identified 17, 18 and 17 hub genes respectively using CytoHubba analysis, of which eight were common among all subgroups (Table S3, Figure 5). Furthermore, using MCODE analysis, clusters with maximum scores were generated and seed gene was determined in the three groups (Figure 6). *MMP9* was identified as seed node with maximum MCODE score in both AMLCN_H and AMLCN_I group (Table S4). Based on the mitochondrial compartment score, CytoHubba and MCODE analyses, a total of 20 DEGs were selected for further validation (Table 2).

Validation of selected DEGs, comparison with TCGA database

In the validation cohort of 143 AML patients, the expression of *SLC25A3*, *SDHC*, *RACK1/GNB2L1*, *FASTKD1*, *ATP5J*, *CLIC1*, *GLUD1*, and *SLC25A29* were found to be significantly upregulated (Figure 7, Table 3) while *FASLG*, *HRK*, *ALAS2*, *SLC25A21*, *CYP1B1*, *SNCA*, *MMP9*, and *OLFM4* were significantly downregulated (Figure 8, Table 3) compared to controls. Two selected genes, *LIG1* and *MRPL51* did not show significant dysregulation while *LONP1* had a reverse expression in the validation compared to transcriptomic expression profile. Upon comparison with TCGA dataset of adult AML patients, similar dysregulation was observed for *ALAS2*, *SLC25A21* and *SLC25A29* genes while a reverse expression pattern was observed for *ATP5J* and *CLIC1* genes; none of the other genes showed significant dysregulation in the TCGA dataset (Table 3).

Mitochondria-related DEGs and mtDNA copy number

On univariable analysis, increased mtDNA copy number was significantly associated with poor event free survival (HR= 2.14; 95%CI (1.39-3.29); p=0.001) and overall survival (HR= 2.77; 95% CI (1.70-4.59); p<0.001) (Figure 9). In patients with increased mtDNA copy number, expression of *SLC25A3*, *SDHC*, *RACK1/GNB2L1* and *FASTKD1*, were significantly higher compared to those with low mtDNA copy number (Figure 10).Exclusive elevated expression of these 4 genes were also observed in transcriptome of samples with high/intermediate mtDNA copy number(AMLCN_H/AMLCN_I) compared to low mtDNA copy number (AMLCN_L).On correlation analysis, these 4 genes along with 2 other genes *CLIC1* and *ATP5J* showed significant positive correlation with mtDNA copy number(Table 4).

Predictive ability of expression of validated DEGs on survival outcome and establishment of the prognostic gene signature

On multivariable analysis, upregulated expression of 2 genes, *SDHC* (HR 1.29; 95% CI (1.14-1.41); p<0.001) and*CLIC1*(HR 1.20; 95% CI (1.04-1.38); p=0.013), and downregulation of *SLC25A29*(HR 0.88; 95% CI (0.83-0.93); p<0.001) were found to be independently predictive of worse OS (Table 5) and they were included for the development of a prognostic gene signature model. All these 3 genes (*SDHC, CLIC1, SLC25A29*) satisfied internal validation by bootstrapping (Table S5), and were finally selected for prognostic model building. Beta coefficient of each of the variables were used for calculation of risk score as follows:

$$Risk\ score = [(0.237 \times \text{Expression}\ SDHC) + (0.179 \times \text{Expression}\ CLIC1) + ((-0.131) \times \text{Expression}\ SLC25A29)] \times 100$$

The formula was used to calculate risk score of all the patients. Risk score median value (10.382) was taken as the cut-off for subgrouping patients into high-risk and low risk group.

Patients with high-risk scores (≥10.382) had inferior OS (HR 1.010; 95% CI (1.007-1.014): p<0.001) compared to those with low-risk score (<10.382) (Figure 11A). Harrel's C-index of the prognostic model was 0.675. The timed AUC of the risk score for 12 months and 18 months survival was 0.747 and 0.736 respectively (Figure 11(B, C).

Association of gene signature-based risk score with event free survival (EFS)

On multivariable Cox regression analysis, upregulation of *SDHC* (HR 1.225; 95% CI (1.100-1.363); p<0.001) and downregulation of *SLC25A29* (HR 0.905; 95% CI (0.860-0.952); p<0.001) were also predictive of worse EFS. We also found that patients with high-risk score had significantly lower EFS as compared to low-risk score patients (HR 1.008; 95% CI (1.001-1.012); p<0.001) (Table 5). Harrel's C-index of prognostic model was 0.626. The timed AUC of the risk score for 12 months and 18 months EFS was 0.617 and 0.612 respectively

Impact of baseline clinical features on survival outcome and association with gene signature model

On univariable Cox regression analysis, ELN intermediate/poor risk and absence of chloroma were significantly associated with inferior OS and only ELN category came out to be an independent prognostic factor in multivariable analysis (Table 6, Figure 11D). Furthermore, on multivariable analysis, both the ELN risk category (p=0.040) and risk score (p<0.001) were found to be independent prognostic factors for OS. We also performed multivariable analysis including mtDNA copy number and observed that all three factors i.e. risk score (p<0.001), ENA risk categories(p=0.012) and mtDNA copy number(p=0.012) were independent prognostic factors for OS (Table S6).

Impact of combined clinical and gene signature model on survival outcome of the cohort

To compare the predictive ability of our gene signature risk score and ELN risk stratification on OS of AML patients, a time dependent AUC was constructed. Harrel's C-index of the

model was 0.59 and the timed AUC of ELN risk category on 12 months and 18 months survival was 0.60 and0.64 respectively (Figure 11E, F). We combined the ELN risk strategy with our risk score and calculated the predictive ability of the model. The Harrel's C-index of the model was 0.688 and the timed AUC of combining ELN risk strategy with gene signature risk score for 12 months and 18 months was 0.761 and 0.765 respectively (Figure 11H and 2I).

Association of gene signature risk score on disease characteristics

We found that a high-risk score was significantly associated with poor risk cytogenetics(p=0.021), absence of RUNX1-RUNX1T1 translocation (p=0.027) and ELN intermediate/poor risk group (p=0.016). Furthermore, the proportion of patients achieving CR was significantly higher in the low-risk group as compared to the high-risk group(p=0.017) (Table 7). On subgroup analysis, it was observed that the mitochondria-related gene signature risk score category was significantly predictive of survival outcome across all clinically relevant subgroups except in those with intermediate/poor-risk karyotype (Figure 12).

Predictive ability of combined gene signature and ELN category model on survival outcome

The predictive ability of gene signature score along with ELN risk stratification on survival outcome of paediatric AML patients was also assessed. Patients with low gene signature score (low risk) belonging to ELN good risk category had significantly better survival outcome (Median OS: Not reached) and predicted 12-months (80%±6%), as well as 18-months (75%±7%) survival. Similarly, patients with high gene signature score (high risk) belonging to ELN intermediate/poor risk category had significantly inferior outcome (4.67 months (0-3.71)) with 12-months and 18-months predicted survival of 33% ± 8% and 25% ± 7% respectively. On the other hand, patients belonging to other groups (ELN intermediate/poor risk and low-risk; ELN good risk and high-risk score) had intermediate

survival outcome (median survival of 27.77-22.90 months respectively) between the two other groups (Figure 11G; Table 8).

External validation of gene signature risk score in TCGA database

Using our risk calculation model, we calculated the risk score in TCGA dataset (n=179) and similarly, patients were further sub-grouped as high-risk score (higher than median) and low risk score (lower than median) based on the median value (43.434). Kaplan Meier analysis showed that patients with a high-risk score (≥43.434) had inferior OS (HR 1.01;95% CI (1.00-1.02); p<0.019) compared to those with a low-risk score (<43.434) (Figure 11J; Table 5). Along with this, poor risk karyotype patients had worse overall survival (HR 1.89; 95% CI (2.95-1.20); p=0.004) compared to patients with good risk or intermediate risk karyotype (7.03 vs 18.96months). On multivariable analysis karyotype (poor vs good risk/intermediate risk) and risk score were found to be independently predictive of (p=0.002; p=0.025 respectively) for worse OS. The timed AUC of risk score for 12-months and 18-months survival in the TCGA dataset were 0.64 and 0.63 respectively (Figure 11K and 11L) and Harrel's C-index of the prognostic model was 0.600.

Discussion

Our study is the first one to identify and validate mitochondria-related DEGs in paediatric AML along with determining their prognostic significance. In paediatric AML patients, we identified and validated 16 mitochondrial DEGs including 8 upregulated and 8 downregulated genes compared to controls. The dysregulated expression of these genes has been previously reported in the pathogenesis of various malignancies(20–23). However, they have not been studied in paediatric AML. Comparison with LAML dataset of TCGA cohort suggests that the mitochondria-related gene expression profile in paediatric AML is likely distinct. Elevated expression of genes like *SLC25A3, FASTKD1, SDHC, ATP5J*, which were observed for the first time in our cohort, are involved in mitochondrial energy

410 metabolism(24–26). Genes like *FASLG*, *HRK* and *SNCA*, which were observed to be
411 downregulated, also play role in prevention of mitochondrial damage and apoptosis inhibition
412 in melanoma/medulloblastoma cell lines(27–29). Preliminary data suggests that
413 downregulation of genes like *MMP9* and *OLFM4*, as observed in our cohort, may aid in
414 AML progression(30,31). The expression of *CYP1B1* is reported to be elevated in various
415 malignancies, however, its expression is downregulated in early age leukaemia, as seen in our
416 cohort(32). These findings suggest that the observed mitochondria-related DEGs likely play
417 crucial role in disease progression in paediatric AML, which needs to be studied further
418 mechanistically.

419 Enhanced mtDNA copy number has been previously reported to be play role on AML
420 initiation, progression as well as predictive of survival outcomes(12,33). Similar to our
421 previous finding, we found that mtDNA copy number were significantly higher and
422 independently predictive of worse survival outcome in this cohort of pediatric AML patients.
423 These findings emphasise the importance of mtDNA copy number as a driver of disease
424 biology. Among the 16 validated mitochondria-related DEGs analysed, we observed that the
425 patients with higher mtDNA copy number had significantly higher expression of *SLC25A3*,
426 *SDHC*, *RACK1*, and *FASTKD1* compared to patients with low mtDNA copy number. While,
427 only a small percentage of mitochondrial proteins are coded by the mitochondrial genome,
428 variations in mtDNA may modulate molecular signals through nuclear-mitochondrial
429 crosstalk, which may promote tumorigenesis by upregulating oncogenes(34,35). This
430 suggests that in paediatric AML, cells with high mtDNA copy number are possibly driven
431 through unique gene expression alterations, influencing disease biology and therapeutic
432 response.

433 Comprehensive gene expression profiling has been extensively used to identify potential
434 prognostic genes in adult AML; however, dysregulation of mitochondria-related gene

expression, especially in children has not been well explored(36–38). Transcriptomic profiling of cytogenetically normal paediatric AML has identified complex genomic rearrangements and/or driver mutations in seemingly normal AML genomes and may even aid risk stratification(39,40). Cai *et al*. developed a 3-gene prognostic risk model for children with AML using NCI TARGET dataset, although it was not externally validated(36). Similarly, Duployez *et al*. and Jiang *et al*. developed leukaemia stem cell score gene signature and immune checkpoint related gene signature respectively in paediatric AML predictive of survival outcomes(4,41). None of the above studies evaluated alterations in mitochondrial gene expressions. Mitochondrial gene expression has been evaluated in other malignancies like ovarian cancer, where a mitochondria-related gene signature, consisting of 8 metabolic genes, has been identified with independent prognostic impact(42).

In this study, we identified exclusive mitochondria-related DEGs in paediatric AML and developed a prognostic gene signature including 3 genes (*SDHC, CLIC1*, and *SLC25A29).* The gene signature risk score was additionally found to be independently predictive of survival along with established ELN risk stratification with improved predictive ability over clinical risk categorization. The risk score was also found to be associated with poor clinical features of AML like the absence of RUNX1-RUNX1T1 translocation or poor-risk cytogenetics. Hence, the gene signature model is able to categorize the heterogenous molecular landscape of AML into clinically meaningful categories along with identification of adverse disease biology. The developed prognostic score also has the potential to identify high-risk subgroup even among those belonging to ELN good risk and vice-versa allowing better upfront risk stratification and personalized treatment decisions.

TCGA LAML dataset has been extensively used for identifying as well as validating prognostic gene signatures in various AML studies(43,44). We used the LAML dataset of TCGA for external validation of our gene signature model and observed that the prognostic

gene signature score was also independently predictive of survival outcome in a large adult cohort as well with predictive ability over and above known clinical predictors. This suggests that the identified DEGs have a prognostic impact in AML across age group.

Our gene signature included 3 mitochondria-related genes i.e., *SDHC*, *CLIC1*, and *SLC25A29*. *SDH* mutations lead to decreased activity of *SDH* with accumulation of succinate and increase in oxidative stress resulting in DNA damage and tumorigenesis(45). In contrast to previous findings, which suggests that the *SDH* gene is inactivated in solid tumors(46), we observed an increased expression of *SDHC* gene in AML which was predictive of worse survival. This is likely because, in contrast to solid malignancies, aggressive leukemias like AML depend on cellular oxidative phosphorylation for proliferation which is supported by upregulation of respiratory complex genes(47). Various studies also suggest dysregulation of chloride ion channels such as the *CLIC1* gene which plays a role in drug resistance and progression of various malignancies(22,48). Although, the role of *CLIC1* in AML is still unexplored, we observed significant upregulation of *CLIC1* in paediatric AML with adverse prognostic impact. The downstream effects of upregulation of *CLIC1* on disease biology of AML need to be further deciphered.

In the current study, we observed an upregulation of *SLC25A29* in our cohort of paediatric AML patients, which is in line with previous studies where it was found to be significantly elevated in multiple malignancies(23). Similar upregulation was also been observed in adult AML patients of TCGA LAML dataset. However, on survival analysis, downregulation of *SLC25A29* was independently predictive of worse OS in our cohort. This finding was consistent even in the external cohort of TCGA LAML dataset, where even though the expression of *SLC25A29* was upregulated, a downregulated expression was predictive of worse survival outcomes. This finding was intriguing and the mechanism by which downregulation of *SLC25A29* drives a worse survival outcome remains unclear. *SLC25A29* is

the main arginine transporter in the mitochondrial membrane(49). Aberrant upregulation of *SLC25A29* may result in transportation of more arginine into mitochondria, promoting synthesis of metabolites like nitric oxide, polyamines, proline and creatine, which are essential for cell survival and proliferation(50). Mitochondria-derived nitric oxide is known to have a dichotomous role in regulation of cancer progression which is influenced by expression of *SLC25A29*likelyaffecting disease outcome(51). The *SLC25* family of genes which encodes for a set of mitochondrial inner membrane carrier proteins, have been identified as a potential biomarker as well as novel therapeutic targets in various malignancies(52). The implications of altered expression of *SLC25A29* on disease biology of AML and its assessment as a therapeutic target is an exciting area of further research.

Our study has certain limitations. Transcriptomic profile and further validation by RTPCR were done in whole isolated mononuclear cell and not in sorted blasts. Initial selection of DEGs were also done from whole RNA sequencing of a limited number of samples, which may lead to a bias in selection, however, external validation of the validated genes confirmed their prognostic impact in an independent cohort.

In conclusion, this is the first study to report a validated set of mitochondria-related DEGs in paediatric AML. We observed that patients with high mtDNA copy number have a unique gene expression pattern possibly affecting disease biology. We developed a 3-gene based mitochondrial gene signature model with ability to predict prognosis in paediatric AML patients over and above established clinical prognostic parameters. The gene signature was also externally validated in a cohort of adult AML patients demonstrating its predictive ability in adult AML as well. Further directions for research include *in vitro* studies for elucidating the role of prognostic genes in leukemogenesis and their evaluation as potential targets for the treatment of paediatric AML.

Data availability statement

510 The sequencing data is publicly available in repository (NCBI-SRA at PRJNA778747) and
511 rest of data is available from the principal investigator on reasonable request.

512 **Acknowledgements**

513 The authors acknowledge the funding support from DST-SERB (Department of Science and
514 Technology - Science and Engineering Research Board), Government of India for this work.
515 (Extramural Research grant: EMR/2016/006376 and Core Research grant:
516 CRG/2021/001887). The authors acknowledge the funding support from ICMR (Indian
517 Council of Medical Research), Government of India for this work (ICMR SRF: 2019-
518 6059/CMB/BMS). The authors also acknowledge every member of paediatric oncology team
519 of our centre including research staff, nurses and dietician for their exemplary clinical
520 services.

521 **Authorship Contribution Statement**

522 Shilpi Chaudhary conceptualized the study, conducted the research, performed data analysis
523 and interpreted results and wrote the manuscript. Shuvadeep Ganguly analysed data,
524 interpreted results and wrote the manuscript. Jayanth Kumar Palanichamy, Archna Singh,
525 Radhika Bakhshi and Anita Chopra conceptualized the study, provided intellectual inputs,
526 administrative support and edited the manuscript. Dibyabhaba Pradhan conducted
527 transcriptome data analysis. Sameer Bakhshi conceptualized the study, provided
528 administrative support, intellectual inputs, interpreted results, wrote and edited the
529 manuscript. All authors have reviewed and approved the final version of the manuscript.

530 **Conflict of interest declaration statement**

531 All authors declare no potential conflicts of interest.

532

References

1. Lonetti A, Pession A, Masetti R. Targeted Therapies for Pediatric AML: Gaps and Perspective [Internet]. Vol. 7, Frontiers in Pediatrics. Frontiers Media S.A.; 2019 [cited 2020 Nov 27]. p. 463. Available from: www.frontiersin.org

2. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [Internet]. Vol. 129, Blood. American Society of Hematology; 2017 [cited 2021 Apr 10]. p. 424–47. Available from: http://ashpublications.org/blood/article-pdf/129/4/424/1402046/blood733196.pdf

3. Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, et al. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia [Internet]. 2020 Mar 1 [cited 2021 Feb 1];34(3):735–45. Available from: https://doi.org/10.1038/s41375-019-0604-8

4. Duployez N, Marceau-Renaut A, Villenet C, Petit A, Rousseau A, Ng SWK, et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Leukemia [Internet]. 2019 Feb 1 [cited 2021 Aug 3];33(2):348–57. Available from: https://haematologica.org/article/view/5869

5. Wagner S, Vadakekolathu J, Tasian SK, Altmann H, Bornhäuser M, Pockley AG, et al. A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. Blood Adv [Internet]. 2019 Apr 23 [cited 2021 Aug 5];3(8):1330–46. Available from: http://www.vizome.org/aml/

6. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy [Internet]. Vol. 11, Nature Chemical Biology. Nature Publishing Group; 2015 [cited 2020 Aug 27]. p. 9–15. Available from: /pmc/articles/PMC4340667/?report=abstract

7. Panina SB, Baran N, Brasil da Costa FH, Konopleva M, Kirienko N V. A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs. Cell Death Dis [Internet]. 2019 Aug 1 [cited 2020 Aug 13];10(8):1–15. Available from: https://doi.org/10.1038/s41419-019-1851-3

8. Al Ageeli E. Alterations of mitochondria and related metabolic pathways in leukemia: A narrative review. Saudi J Med Med Sci [Internet]. 2020 [cited 2020 Aug 16];8(1):3. Available from: /pmc/articles/PMC6945320/?report=abstract

9. Tyagi A, Pramanik R, Bakhshi R, Singh A, Vishnubhatla S, Bakhshi S. Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia. Int J Hematol [Internet]. 2019 Aug 5 [cited 2020 Jul 21];110(2):205–12. Available from: https://doi.org/10.1007/s12185-019-02666-2

10. Tyagi A, Pramanik R, Vishnubhatla S, Bakhshi R, Bakhshi S. Prognostic impact of mitochondrial DNA D-loop variations in pediatric acute myeloid leukemia. Oncotarget [Internet]. 2019 Feb 1 [cited 2020 Aug 14];10(13):1334–43. Available from: /pmc/articles/PMC6407682/?report=abstract

11. Sharawat SK, Bakhshi R, Vishnubhatla S, Bakhshi S. Mitochondrial D-loop variations in paediatric acute myeloid leukaemia: A potential prognostic marker. Br J Haematol [Internet]. 2010 May 1 [cited 2021 Apr 12];149(3):391–8. Available from: http://doi.wiley.com/10.1111/j.1365-2141.2010.08084.x

12. Chaudhary S, Ganguly S, Palanichamy JK, Singh A, Bakhshi R, Jain A, et al. PGC1A driven enhanced mitochondrial DNA copy number predicts outcome in pediatric acute myeloid leukemia. Mitochondrion [Internet]. 2021 May 1 [cited 2021 Apr 14];58:246–54. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1567724921000453

13. Arora S, Pushpam D, Tiwari A, Choudhary P, Chopra A, Gupta R, et al. Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt

583 from a tertiary care center in India. Pediatr Transplant [Internet]. 2020 [cited 2021 Apr
584 12]; Available from: https://pubmed.ncbi.nlm.nih.gov/33142026/
585 14. Tyagi A, Pramanik R, Chaudhary S, Chopra A, Bakhshi S. Cytogenetic Profiles of 472
586 Indian Children with Acute Myeloid Leukemia. Indian Pediatr. 2018;55(6):469–73.
587 15. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al.
588 STRING v9.1: protein-protein interaction networks, with increased coverage and
589 integration. Nucleic Acids Res. 2012 Nov;41(D1):D808–15.
590 16. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: Identifying hub
591 objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(4):S11.
592 17. Bader GD, Hogue CWV. An automated method for finding molecular complexes in
593 large protein interaction networks. BMC Bioinformatics. 2003 Jan;4:2.
594 18. Binder JX, Pletscher-Frankild S, Tsafou K, Stolte C, O'Donoghue SI, Schneider R, et
595 al. COMPARTMENTS: Unification and visualization of protein subcellular
596 localization evidence. Database [Internet]. 2014 [cited 2021 Jun 3];2014. Available
597 from: /pmc/articles/PMC3935310/
598 19. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and
599 normal gene expression profiling and interactive analyses. Nucleic Acids Res
600 [Internet]. 2017 Jul 3 [cited 2021 Jun 4];45(W1):W98–102. Available from:
601 https://pubmed.ncbi.nlm.nih.gov/28407145/
602 20. Li J-J, Xie D. RACK1, a versatile hub in cancer. Oncogene 2015 3415 [Internet]. 2014
603 Jun 2 [cited 2021 Jul 12];34(15):1890–8. Available from:
604 https://www.nature.com/articles/onc2014127
605 21. Oehler VG, Ka YY, Choi YE, Bumgarner RE, Raftery AE, Radich JP. The derivation
606 of diagnostic markers of chronic myeloid leukemia progression from microarray data.
607 Blood. 2009;114(15):3292–8.

608 22. Lee JR, Lee JY, Kim HJ, Hahn MJ, Kang JS, Cho H. The inhibition of chloride
609 intracellular channel 1 enhances Ca2+ and reactive oxygen species signaling in A549
610 human lung cancer cells. Exp Mol Med [Internet]. 2019 Jul 1 [cited 2020 Sep
611 25];51(7):1–11. Available from: https://doi.org/10.1038/s12276-019-0279-2
612 23. Zhang H, Wang Q, Gu J, Yin L, Liang S, Wu L, et al. Elevated mitochondrial
613 SLC25A29 in cancer modulates metabolic status by increasing mitochondria-derived
614 nitric oxide. Oncogene. 2018 May;37(19):2545–58.
615 24. Kolbe HVJ, Costello D, Wong A. Mitochondrial phosphate transport. Large scale
616 isolation and characterization of the phosphate transport protein from beef heart
617 mitochondria. J Biol Chem [Internet]. 1984 [cited 2021 Jul 9];259(14):9115–20.
618 Available from: https://www.jbc.org/article/S0021-9258(17)47273-5/abstract
619 25. Nazar E, Khatami F, Saffar H, Tavangar SM. The Emerging Role of Succinate
620 Dehyrogenase Genes (SDHx) in Tumorigenesis. Int J Hematol Stem Cell Res
621 [Internet]. 2019 [cited 2021 Jul 12];13(2):72. Available from:
622 /pmc/articles/PMC6660475/
623 26. AA J, J P, MA de la F, JC M, P A, M S. The FASTK family of proteins: emerging
624 regulators of mitochondrial RNA biology. Nucleic Acids Res [Internet]. 2017 Nov 2
625 [cited 2021 Jul 12];45(19):10941–7. Available from:
626 https://pubmed.ncbi.nlm.nih.gov/29036396/
627 27. M C, W W, J M, P Y, K W. High glucose induces mitochondrial dysfunction and
628 apoptosis in human retinal pigment epithelium cells via promoting SOCS1 and
629 Fas/FasL signaling. Cytokine [Internet]. 2016 Feb 1 [cited 2021 Jul 13];78:94–102.
630 Available from: https://pubmed.ncbi.nlm.nih.gov/26700587/
631 28. Li Y, Yu Z, Jiang T, Shao L, Liu Y, Li N, et al. SNCA, a novel biomarker for Group 4
632 medulloblastomas, can inhibit tumor invasion and induce apoptosis. Cancer Sci

[Internet]. 2018 Apr 1 [cited 2021 Jul 13];109(4):1263. Available from: /pmc/articles/PMC5891175/

29. Rizvi F, Heimann T, Herrnreiter A, O'Brien WJ. Mitochondrial Dysfunction Links Ceramide Activated HRK Expression and Cell Death. PLoS One [Internet]. 2011 [cited 2021 Jul 13];6(3):e18137. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018137

30. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metalloproteinases (MMPS) and tissue inhibitors of MMP in acute leukaemia: Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol [Internet]. 2002 Jun 1 [cited 2021 Jan 25];117(4):835–41. Available from: http://doi.wiley.com/10.1046/j.1365-2141.2002.03510.x

31. Liu W, Lee HW, Liu Y, Wang R, Rodgers GP. Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. Blood [Internet]. 2010 Dec 2 [cited 2021 Jul 13];116(23):4938–47. Available from: https://www.meta.org/papers/olfactomedin-4-is-a-novel-target-gene-of-retinoic/20724538

32. Lopes BA, Emerenciano M, Gonçalves BAA, Vieira TM, Rossini A, Pombo-de-Oliveira MS. Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 are associated with early age acute leukemia. Kanungo J, editor. PLoS One [Internet]. 2015 May 18 [cited 2021 Feb 1];10(5):e0127308. Available from: https://dx.plos.org/10.1371/journal.pone.0127308

33. Kang MG, Kim YN, Lee JH, Szardenings M, Baek HJ, Kook H, et al. Clinicopathological implications of mitochondrial genome alterations in pediatric acute myeloid leukemia. Ann Lab Med [Internet]. 2016 Mar 1 [cited 2020 Jul

23];36(2):101–10. Available from: https://pubmed.ncbi.nlm.nih.gov/26709256/

34. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, et al. A Mitochondrial Protein Compendium Elucidates Complex I Disease Biology. Cell. 2008 Jul 11;134(1):112–23.

35. Horan MP, Cooper DN. The emergence of the mitochondrial genome as a partial regulator of nuclear function is providing new insights into the genetic mechanisms underlying age-related complex disease [Internet]. Vol. 133, Human Genetics. Hum Genet; 2014 [cited 2021 Jul 9]. p. 435–58. Available from: https://pubmed.ncbi.nlm.nih.gov/24305784/

36. Cai Z, Wu Y, Zhang F, Wu H. A three-gene signature and clinical outcome in pediatric acute myeloid leukemia. Clin Transl Oncol [Internet]. 2020 Aug 29 [cited 2021 Feb 1]; Available from: http://link.springer.com/10.1007/s12094-020-02480-x

37. Duployez N, Marceau-Renaut A, Villenet C, Petit A, Rousseau A, Ng SWK, et al. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia [Internet]. 2019 Feb 1 [cited 2021 Feb 1];33(2):348–57. Available from: https://doi.org/10.1038/s41375-018-0227-5

38. Nguyen CH, Glüxam T, Schlerka A, Bauer K, Grandits AM, Hackl H, et al. SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness. Sci Rep [Internet]. 2019 Dec 1 [cited 2021 Feb 1];9(1):1–13. Available from: https://doi.org/10.1038/s41598-019-45579-0

39. Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, et al. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv [Internet]. 2019 Oct 22 [cited 2021 Aug 16];3(20):3157–69. Available from: /pmc/articles/PMC6849955/

40. Balgobind B V., van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink

IHI, Arentsen-Peters STJCM, et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica. 2011 Feb;96(2):221–30.

41. Jiang F, Wang XY, Wang MY, Mao Y, Miao XL, Wu CY, et al. An Immune Checkpoint-Related Gene Signature for Predicting Survival of Pediatric Acute Myeloid Leukemia. J Oncol. 2021;2021.

42. Wang L, Li X. Identification of an energy metabolism-related gene signature in ovarian cancer prognosis. Oncol Rep [Internet]. 2020 Jun 1 [cited 2021 Feb 2];43(6):1755–70. Available from: http://www.affymetrix.

43. Zhang Y, Ma S, Wang M, Shi W, Hu Y. Comprehensive Analysis of Prognostic Markers for Acute Myeloid Leukemia Based on Four Metabolic Genes. Front Oncol. 2020 Sep 29;0:1990.

44. Huang R, Liao X, Li Q. Identification and validation of potential prognostic gene biomarkers for predicting survival in patients with acute myeloid leukemia. Onco Targets Ther [Internet]. 2017 Nov 2 [cited 2021 Aug 3];10:5243. Available from: /pmc/articles/PMC5679677/

45. Zhao T, Mu X, You Q. Succinate: An initiator in tumorigenesis and progression [Internet]. Vol. 8, Oncotarget. Impact Journals, LLC; 2017 [cited 2021 Aug 16]. p. 53819–28. Available from: /pmc/articles/PMC5581152/

46. Li J, Liang N, Long X, Zhao J, Yang J, Du X, et al. SDHC-related deficiency of SDH complex activity promotes growth and metastasis of hepatocellular carcinoma via ROS/NFκB signaling. Cancer Lett. 2019 Oct;461:44–55.

47. Panina SB, Pei J, Kirienko N V. Mitochondrial metabolism as a target for acute myeloid leukemia treatment [Internet]. Vol. 9, Cancer & Metabolism. Springer Science and Business Media LLC; 2021 [cited 2021 May 26]. p. 1–25. Available from:

https://doi.org/10.1186/s40170-021-00253-w

48. He YM, Zhang ZL, Liu QY, Xiao YS, Wei L, Xi C, et al. Effect of CLIC1 gene silencing on proliferation, migration, invasion and apoptosis of human gallbladder cancer cells. J Cell Mol Med. 2018 May;22(5):2569–79.

49. Porcelli V, Fiermonte G, Longo A, Palmieri F. The human gene SLC25A29, of solute carrier family 25, encodes a mitochondrial transporter of basic amino acids. J Biol Chem. 2014 May;289(19):13374–84.

50. Keshet R, Erez A. Arginine and the metabolic regulation of nitric oxide synthesis in cancer [Internet]. Vol. 11, DMM Disease Models and Mechanisms. Company of Biologists; 2018 [cited 2021 Aug 19]. Available from: /pmc/articles/PMC6124554/

51. Ghafourifar P, Cadenas E. Mitochondrial nitric oxide synthase. Vol. 26, Trends in Pharmacological Sciences. Elsevier Ltd; 2005. p. 190–5.

52. Rochette L, Meloux A, Zeller M, Malka G, Cottin Y, Vergely C. Mitochondrial SLC25 carriers: Novel targets for cancer therapy. Vol. 25, Molecules. MDPI AG; 2020.

725 **Figures**

Figure 1



726
727 **Figure 1. Workflow of the study:** Study workflow showing flow of patients from enrolment to
728 RNA sequencing, identification of mitochondria- related DEGs, development and validation of novel
729 3-gene based Risk score.

Figure 2



730

731 **Figure 2**: Workflow of RNA sequencing data analysis using various bioinformatic tools

732

733

734

Figure 3



Figure 3: Volcano plots representing all dysregulated transcripts among AMLCN_H (A), AMLCN_I (B) and AMLCN_L (C) groups compared to controls. Green dots represent significantly differentially expressed transcripts in the three subgroups of AML compared to controls. High AMLCN_H (more than 75th percentile); intermediate AMLCN_I (50th to 75th percentile) and low AMLCN_L (lower than 50th percentile) relative mitochondrial DNA copy number

Figure 4



743

744

745 **Figure 4:** Venn diagram representing mitochondrial associated differentially expressed genes (DEGs)
746 among three groups of AML (AMLCN_H; AMLCN_I and AMLCN_L). High AMLCN_H (more
747 than 75th percentile); intermediate AMLCN_I (50th to 75th percentile) and low AMLCN_L (lower than
748 50th percentile) relative mitochondrial DNA copy number

749

750

751

Figure 5



752

753

754 **Figure 5**: Hub gene based on Maximal Clique Centrality (MCC) (A): AMLCN_H; (B) AMLCN_I;
755 (C) AMLCN_L. High AMLCN_H (more than 75th percentile); intermediate AMLCN_I (50th to 75th
756 percentile) and low AMLCN_L (lower than 50th percentile) relative mitochondrial DNA copy number

757

758

Figure 6



Figure 6: MCODE (molecular complex detection) analysis showing most interactive clusters among A: (A): AMLCN_H; (B) AMLCN_I; (C) AMLCN_L. High AMLCN_H (more than 75th percentile); intermediate AMLCN_I (50th to 75th percentile) and low AMLCN_L (lower than 50th percentile) relative mitochondrial DNA copy number

Figure 7



Figure 7: Validation of selected upregulated differentially expressed genes (DEGs) in patients as compared to controls. *SLC25A3*, *SLC25A29*, *SDHC*, *FASTKD1*, *GLUD1*, *RACK1*, *ATP5J* and *CLIC1* were significantly upregulated in pediatric AML patients (n=143) compared to controls (n=50). *: P<0.05; **: P< 0.01; ***: P<0.001; ****: P<0.0001.



Figure 8: Validation of selected downregulated differentially expressed genes (DEGs) in patients as compared to controls. *FASLG*, *CYP1B1*, *HRK*, *ALAS2*, *SLC25A21*, *MMP9*, *SNCA* and *OLFM4* were significantly downregulated in pediatric AML patients (n=143) compared to controls (n=50) *: P<0.05; **: P< 0.01; ***: P<0.001; ****: P<0.0001

Figure 9



785

786 **Figure 9**: Kaplan Meier curves representing association of mtDNA copy number with (A) event free
787 survival and (B) overall survival of pediatric AML patients

788

789

Figure 10



790

791 **Figure 10:** Subgroup analysis of acute myeloid leukemia showing exclusive deregulation of validated
792 genes among AMLCN_L and AMLCN_H group. The expression of *SLC25A3*(A), *SDHC*(B),
793 *RACK1*(C) and *FASTKD1*(D) were significantly higher in AMLCN_H group as compared to
794 AMLCN_L

795

796

Figure 11



797

Figure 11: Kaplan Meier curves representing association of mtDNA copy number with (A) event free survival and (B) overall survival of pediatric AML patients **Figure 11.A 3-gene based gene signature stratifies survival in pediatric and adult AML patients along with clinically established European LeukemiaNet (ELN) risk categories.** (A) Kaplan Meier estimates of overall survival in pediatric AML patient's subgroup into high Risk-score and low Risk-score. (B) and (C) AUC curves quantify the ability of our 3-gene based risk score to predict outcome in individual patients (specificity and sensitivity) within the first 12 months(B) and 18 months(C) of treatment initiation respectively. (D) Kaplan Meier estimates of overall survival in pediatric AML patient's subgroup into ELN good risk and ELN intermediate or poor risk categories. (E) and (F) AUC curves quantify the ability of ELN risk categories to predict outcome in individual patients (specificity and sensitivity) within the first 12 months (E) and 18 months(F) of treatment initiation respectively. (G) Kaplan Meier estimates of overall survival in pediatric AML patient's subgroup by combining ELN risk categories with our 3 gene-based risk score. (H) and (I) AUC curves quantify the ability of combined model of ELN risk categories and our 3 gene-based risk score to predict outcome in individual patients (specificity and sensitivity) within the first 12 months(H) and 18 months(I) of treatment initiation respectively. (J) Kaplan Meier estimates of overall survival in external adult The Cancer Genome Atlas (TCGA) AML patient's subgroup into high Risk-score and low Risk-score using our 3 gene-based gene signature model. (K) and (L) AUC curves quantify the ability of our 3-gene based risk score to predict outcome in individual patients of TCGA adult AML datasets (specificity and sensitivity) within the first 12 months(K) and 18 months(L) of treatment initiation respectively. AUC = 1.0 would denote perfect prediction, and AUC = 0.5 would denote no predictive ability.

832



833

834 **Figure 12:** Forest plot showing the impact of mitochondrial prognostic gene signature risk score
835 category on survival outcome in various clinically relevant subgroups of pediatric Acute myeloid
836 leukemia

837

838

839

840

841 **Table 1: Baseline characteristic features of pediatric AML patients (n=143)**

Characteristics	**Number (%)**
Median age (years)	10 (0.8-18)
Sex	
Male	87 (60.8)
Female	56 (39.2)
Haematological parameters	
Median haemoglobin, (g/dL)	7.4 (2.1-14.6)
Median total leucocyte count, ($\times 10^3/\mu L$)	24.38 (0.76-314.3)
Hyperleukocytosis, ($>50\times 10^3/\mu L$)	45 (31.46)
Median platelet count, ($\times 10^3/\mu L$)	35.00(4-276)
Clinical features at presentation	
Fever	112(78.3)
Chloroma	27 (18.9)
Cytogenetics (n=130)	
Normal	36 (27.5)
t(8;21) & inv (16)*	52 (39.7)
Complex karyotype	8 (6.1)
Other	19 (14.5)
Failed cytogenetics	16(12.2)
Molecular analysis (n= 122)	
FLT3 ITD	17 (13.8)
RUNX1-RUNX1T1	53 (43.1)
CBFB-MYH11	6 (4.9)
NPM1	5 (4.1)
Negative	41 (33.6)
ELN risk stratification (n=134)**	
Good	67 (50)
Intermediate	37 (27.6)
Poor	30 (22.4)
Complete remission (n=143)	
Achieved	104 (72.7%)
Not achieved	39 (27.3%)

842 * t(8;21)= t(8;21)(q22;q22) *RUNX1-RUNX1T1*; inv(16)= inv(16)(p13.1;q22) *CBFB-MYH11*

**ELN risk stratification was done using both cytogenetics and molecular markers in 134 patients. However, for 12 patients risk stratification was done with only cytogenetics and in 20 patients, it was done by only molecular analysis.

Median values were reported with range

n: number of patients; AML: Acute Myeloid Leukemia; Normal cytogenetics: 46,XX/46,XY; Failed cytogenetics: metaphases could not be isolated; *FLT3 ITD*: FMS-like tyrosine kinase internal tandem duplication; *RUNX1-RUNX1T1*: runt-related transcription factor 1-RUNX1 partner transcriptional co-repressor 1 fusion transcript; *CBFB-MYH11*: core binding factor beta-myosin heavy chain 11 fusion transcript; *NPM1*: Nucleophosmin 1; ELN: European LeukemiaNet.

Table 2: List of genes selected for validation among all the groups based on mitochondrial compartment score, *Cytohubba* and *MCODE*

S no.	Gene name	Compartment mitochondria score (0-5)	Groupwise expression	Expression in RNA seq data
1	*SLC25A3*	5	AMLCN_H	Upregulation
2	*LONP1*	5	AMLCN_H	Downregulation
3	*SDHC*	5	AMLCN_H	Upregulation
4	*GNB2L1/RACK1*	4.2	AMLCN_H	Upregulation
5	*FASTKD1*	5	AMLCN_I	Upregulation
6	*MRPL51*	5	AMLCN_I	Downregulation
7	*ATP5J*	5	AMLCN_I	Upregulation
8	*FASLG*	2.64	AMLCN_L	Downregulation
9	*CLIC1*	3.12	AMLCN_L	Upregulation
10	*HRK*	5	Common in all AML samples	Downregulation
11	*ALAS2*	5	Common in all AML samples	Downregulation
12	*SLC25A21*	5	Common in all AML samples	Downregulation
13	*CYP1B1*	4.35	Common in all AML samples	Downregulation
14	*GLUD1*	5	Common in AMLCN_H & AMLCN_I	Upregulation
15	*SLC25A29*	5	Common in AMLCN_H & AMLCN_I	Upregulation
16	*LIG1*	3.6	Common in AMLCN_H & AMLCN_I	Downregulation
17	*SNCA*	4.6	Common in AMLCN_L & AMLCN_H	Downregulation
18	*DHFR*	4.7	Common in AMLCN_L & AMLCN_H	Downregulation
19	*MMP9*	2.8	Hub gene and Seed gene in MCODE cluster of AMLCN_H & AMLCN_I	Downregulation
20	*OLFM4*	5	MCODE cluster gene	Downregulation

All the genes selected for validation are listed in the table. Selection of genes were based on their mitochondrial compartment score as determined by *Cytoscape*. *SLC25A3*, *LONP1*, *SDHC*, *GNB2L1/RACK1* were selected exclusively from AMLCN_H subgroup. Three genes (*FASTKD1, MRPL51 AND ATP6J*) belongs to AMLCN_I subgroup and two genes *(FASLG & CLIC1*) were selected from AMLCN_L subgroup. Furthermore, three genes (*SLC25A29, GLUD1* and *LIG1*) which were common among AMLCN_H and AMLCN_I and two genes, *DHFR* and *SNCA* were selected from the common genes among AMLCN_H and AMLCN_L cohort. *MMP9* and *OLFM4* were selected based on the Hub gene and MCODE analysis.

866 **Table 3: Median expression of validated genes in patients (n=143) compared to controls(n=50)**
867 **and their comparison with TCGA LAML dataset(n=179)**

S.no.	Gene list	Expression	Median expression (IQR)[#]	P value[##]	Expression in our cohort	Expression in TCGA dataset (LAML)*
1.	***SLC25A3***	Patients	7.45E-04 (5.46E-04-1.08E-03)	< 0.0001	Overexpression	Non-significant
		Controls	4.83E-04(3.08E-04-6.95E-04)			
2.	***SDHC***	Patients	1.03E-04(7.21E-05-1.66E-04)	< 0.0001	Overexpression	Non-significant
		Controls	5.13E-05(3.39E-05-7.81E-05)			
3.	***RACK1/ GNB2L1***	Patients	1.56E-02(1.07E-02-2.26E-02)	< 0.0001	Overexpression	Non-significant
		Controls	6.43E-03(4.12E-03-9.42E-03)			
4.	***FASTKD1***	Patients	6.10E-04(3.75E-04-1.09E-03)	< 0.0001	Overexpression	Non-significant
		Controls	2.71E-04(1.60E-04-5.06E-04)			
5.	***ATP5J***	Patients	2.67E-06(1.48E-06-4.23E-06)	< 0.0001	Overexpression	Downregulation
		Controls	5.63E-07(1.44E-07 -1.04E-06)			
6.	***FASLG***	Patients	1.24E-05(5.82E-06-2.23E-05)	< 0.0001	Downregulation	Non-significant
		Controls	2.83E-05(1.72E-05-5.11E-05)			
7.	***CLIC1***	Patients	9.63E-04(6.70E-04-1.48E-03)	< 0.0001	Overexpression	Downregulation
		Controls	5.46E-04(3.68E-04-7.91E-04)			
8.	***HRK***	Patients	2.99E-06(1.30E-06-7.32E-06)	< 0.0001	Downregulation	Non-significant
		Controls	2.64E-05(7.26E-06-4.44E-05)			
9.	***ALAS2***	Patients	9.00E-05(1.68E-05-4.16E-04)	< 0.0001	Downregulation	Downregulation
		Controls	7.61E-04(4.68E-04-1.71E-03)			
10.	***SLC25A21***	Patients	2.27E-06(6.51E-07-7.02E-06)	< 0.0001	Downregulation	Downregulation
		Controls	8.28E-05(3.86E-05-1.32E-04)			
11.	***CYP1B1***	Patients	4.87E-07(1.94E-07-1.87E-06)	< 0.0001	Downregulation	Non-significant
		Controls	4.57E-06(3.22E-06-1.05E-05)			
12.	***GLUT1***	Patients	5.46E-04(3.88E-04-8.10E-04)	< 0.0001	Overexpression	Non-significant
		Controls	2.65E-04(1.91E-04-4.08E-04)			
13.	***SLC25A29***	Patients	3.48E-04(1.94E-04-6.53E-04)	< 0.0001	Overexpression	Upregulation
		Controls	7.30E-05(5.35E-05-1.26E-04)			
14.	***SNCA***	Patients	5.73E-05(2.30E-05-1.59E-04)	0.0023	Downregulation	Non-significant
		Controls	1.06E-04(5.29E-05-2.25E-04)			
15.	***DHFR***	Patients	5.01E-04(2.58E-04-7.72E-04)	0.0115	Non- significant	Non-significant
		Controls	7.15E-04(4.32E-04-1.25E-03)			
16.	***MMP9***	Patients	2.70E-05(7.74E-06-7.15E-05)	< 0.0001	Downregulation	Non-significant
		Controls	9.05E-04(3.79E-04-1.37E-03)			
17.	***OLFM4***	Patients	3.78E-05(1.16E-05-1.47E-04)	< 0.0001	Downregulation	Non-significant
		Controls	9.37E-04(4.46E-04-2.54E-03)			
18.	***LIG1***	Patients	1.57E-04(9.12E-05- 2.46E-04)	0.8696	Non- significant	Non-significant
		Controls	1.38E-04(1.06E-04- 2.46E-04)			
19.	***MRPL51***	Patients	6.95E-04(5.46E-04-1.07E-03)	0.0116	Non- significant	Downregulation
		Controls	5.25E-04 (3.56E-04-1.00E-03)			
20.	***LONP1***	Patients	2.93E-04(2.10E-04-4.11E-04)	< 0.0001[**]	Upregulation	Downregulation
		Controls	1.79E-04(1.03E-04-2.59E-04)			

[#]IQR= Interquartile Range

[##]Level of significance was set by adjusting alpha error for multiple comparisons by Bonferroni correction ($p < (0.05/20)$ i.e. $p<0.0025$ were considered as significant)

*LAML = adult AML data available on TCGA (The Cancer Genome Atlas) database accessed from *Gepia*

** The expression of *LONP1* showed reverse expression trend in validation cohort when compared to RNA sequencing data of test cohort hence considered not validated.

877 **Table 4: List of genes showing significant correlation with mitochondrial DNA copy number**
878 **using Pearson's correlation**

Gene name	Mitochondrial DNA Copy number (n=143)	
	Correlation coefficient (r)	p value
ATP5J	0.133	0.024
FASTKD1	0.158	0.008
CLIC1	0.165	0.005
RACK1/GNB2L1	0.174	0.003
SDHC	0.172	0.004
SLC25A3	0.155	0.009

879 n= number of patients

880

881

882

Table 5: Impact of expression of individual genes and overall risk score on overall survival and event free survival of the test cohort (pediatric cohort) and overall survival in validation cohort (TCGA adult LAML cohort)

Gene Name	Overall survival (Pediatric cohort) n=143		Overall survival (TCGA adult LAML cohort) n=179		Event Free Survival (Pediatric cohort) n=143	
	Hazard Ratio (95% CI)	P value	Hazard Ratio (95% CI)	P value	Hazard Ratio (95% CI)	P value
SDHC	1.29(1.14-1.41)	<0.001	0.994(0.941-1.050)	0.826	1.225(1.100-1.363)	<0.001
SLC25A29	0.88(0.83-0.93)	<0.001	0.988(0.981-0.996)	0.003	0.905(0.860-0.952)	<0.001
CLIC1	1.20(1.04-1.38)	0.013	1.002(1.00-1.004)	0.069	1.136(0.984-1.312)	0.082
Risk Score	1.010(1.007-1.014)	<0.001	1.011(1.002-1.021)	0.019	1.008(1.001-1.012)	<0.001

CI: Confidence interval; n= number of patients; TCGA The cancer genome atlas; LAML Adult AML dataset

903 **Table 6: Univariable and multivariable analysis of clinical features with overall survival**

Variables (n=143)	Categories (n)	Univariable analysis			Multivariable analysis	
		Median	Hazard (95% CI)	p value	Hazard (95% CI)	p value
Age(years)	≤10 (64)	20.63	0.98(0.63-1.52)	0.93	-	-
	>10(79)	21.93				
Gender	Male (87)	15.07	0.72(0.45-1.143)	0.16	-	-
	Female (56)	40.23				
Total leukocyte count (/mm^3)	<50000(98)	23.77	0.8(0.517-1.238)	0.32	-	-
	>50000(45)	13.88				
Platelets (/µL)	≤ 50000(92)	19.53	0.94(0.59-1.48)	0.789	-	-
	>50000(51)	23.33				
Haemoglobin(g/dl)	≤8(95)	13.87	0.73(0.47-1.12)	0.16	-	-
	>8(48)	24.87				
Fever	Negative (26)	Not reached	1.52(0.82-2.83)	0.18	-	-
	Positive (112)	19.53				
Chloroma (n=132)	Negative (105)	20.63	0.56(0.29-1.07)	0.083	1.45(0.74-2.84)	0.27
	Positive (27)	Not reached				
ELN Risk group (n=134)	Good (67)	40.23	1.95(1.23-3.09)	0.004	0.59(0.36-0.98)	0.041
	Others (67)	12.27				

904 CI: Confidence interval; ELN: European LeukemiaNet.

905

906

907

908

909 **Table 7: Association of 3-gene risk score with clinical and demographic parameters**

Characteristics (n=143)	**Risk score Low (%) (n=71)**	**Risk score High (%) (n=72)**	χ^2	**P value**
Age (years)				
<10 Years (64)	26(36.6)	38(52.8)	3.775	0.052
≥10 years (79)	45(63.4)	34(47.2)		
Sex				
Male (87)	42(59.2)	45(62.5)	0.168	0.682
Female (56)	29(40.8)	27(37.5)		
Hyperleukocytosis, (>50×10^3/µL)				
TLC <50×10^3/µL (98)	53(74.6)	45(62.5)	2.446	0.118
TLC≥50×10^3/µL (45)	18(25.4)	27(37.5)		
Fever(n=138)				
Negative (26)	17(24.6)	9(13.0)	3.033	0.082
Positive (112)	52(75.4)	60(87.0)		
Chloroma				
Negative (116)	57(80.3)	59(81.9)	1.781	0.182
Positive (27)	14(19.7)	13(18.1)		
Cytogenetics (n=130) *				
Good Risk (50)	32(54.2)	18(32.7)	5.349	0.021
Others (64)	27(45.8)	37(67.3)		
Molecular analysis (n= 122) **				
FLT3ITD				
Negative (105)	54(87.1)	51(85.0)	0.112	0.738
Positive (17)	8(12.9)	9(15.0)		
RUNX1-RUNX1T1				
Negative (69)	29(46.8)	40(66.7)	4.911	0.027
Positive (53)	33(53.2)	20(33.3)		
***CBFB-MYH11* #**				
Negative (113)	58(93.5)	55(91.7)	-	1.00##
Positive (6)	3(4.83)	3(5.0)		
NPM1				
Negative (117)	61(98.4)	56(93.3)	-	0.203##
Positive (5)	1(1.61)	4(6.7)		

ELN Risk stratification (n=134) ***				
Good Risk (67)	41(60.3)	26(39.4)	5.852	0.016
Intermediate and poor risk (67)	27(39.7)	40(60.6)		
Complete remission (n=143)				
Achieved (104)	58(81.7)	46(63.9)	5.711	0.017
Not achieved (39)	13(18.3)	26(36.1)		

*Cytogenetics failed (n=16) and not done in n=13 cases.

** Molecular analysis was not done in 19 cases; molecular mutation was absent in n=43 cases

#*CBFB-MYH11* mutation was assessed in n=119 cases

[##] Fisher's Exact Test

***ELN (European LeukemiaNet) risk stratification was done using both cytogenetics and molecular markers in 134 patients. However, 12 patients risk stratification was done with only cytogenetics and in 20 patients, it was done by only molecular analysis

χ 2: Chi square value; TLC: Total leukocyte count; *FLT3 ITD*: FMS-like tyrosine kinase internal tandem duplication; *RUNX1-RUNX1T1*: runt-related transcription factor 1-RUNX1 partner transcriptional co-repressor 1 fusion transcript; *CBFB-MYH11*: core binding factor beta-myosin heavy chain 11 fusion transcript; *NPM1*: Nucleophosmin 1;

Table 8: Predictive ability of combined gene risk score group and ELN risk category on survival outcome in pediatric AML cohort

Variables(n)	HR (95%CI)	P Value	P value (overall)	Median OS (months)	Predicted 12 months survival	Predicted18 months survival
ELN Good risk & gene signature risk group Low (41)	1	--	<0.001	Not reached	80%±6%	75%±7%
ELN Others & gene signature risk group Low (27)	1.58 (0.78-3.21)	0.20	-	27.77(±7.82)	74% ±8%	58% ±10%
ELN Good risk & gene signature risk group High (26)	2.12 (1.06-4.26)	0.034	-	22.90(±8.31)	54% ±10%	44% ±10%
ELN Others & gene signature risk group High (40)	3.83 (2.07-7.07)	<0.001	-	4.67(±3.71)	33% ± 8%	25% ± 7%

HR: Hazard Ratio; CI: Confidence interval; OS: overall survival; ELN: European LeukemiaNet; AML: Acute myeloid leukemia